Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals international, plc - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Kiniksa Pharmaceuticals International (KNSA) has drawn investor attention after its recent trading session, with the stock closing at $45.15. The move comes against a backdrop of ongoing revenue and net income generation in biopharmaceutical therapies. See our latest analysis for Kiniksa Pharmaceuticals International. While the share price has eased, with a 1-day share price return showing a 3.98% decline and a 7-day share price return showing a 2.50% decline, the 1-year total shareholder return of 95.62% and 3-year total shareholder return of about 4x indicate that momentum has been strong over a longer horizon. If Kiniksa's move has you thinking about what else could be setting up for strong future stories in healthcare, it may be worth reviewing 35 healthcare AI stocks With Kiniksa trading at $45.15 against a price target of $57.38 and an indicated intrinsic discount of about 74%, the key question is whether the stock is still undervalued or whether the market is already p
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wedbush from $53.00 to $58.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa's Heart's Home Campaign Puts ARCALYST Growth Prospects In Focus [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis [Yahoo! Finance]Yahoo! Finance
KNSA
Earnings
- 2/24/26 - Miss
KNSA
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form DEF
- KNSA's page on the SEC website